Clinical trial
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With…
NCT00078598 · Corixa Corporation, Industry · Unknown status
Key facts
| NCT number | NCT00078598 |
|---|---|
| Title | A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma |
| Official title | A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma |
| Lead sponsor | Corixa Corporation, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Rituximab or Iodine I 131 Tositumomab Therapy |
| Enrollment | 506 |
| Start date | Apr 1, 2004 |
| First posted | Mar 3, 2004 |
| Last update posted | Nov 9, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: